Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Evaluation of liquid from… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers

Artikel i vetenskaplig tidskrift
Författare Y. Wang
L. Li
C. Douville
J. D. Cohen
T. T. Yen
I. Kinde
Karin Sundfeldt
S. K. Kjær
R. H. Hruban
I. M. Shih
T. L. Wang
R. J. Kurman
S. Springer
J. Ptak
M. Popoli
J. Schaefer
N. Silliman
L. Dobbyn
E. J. Tanner
A. Angarita
Maria Lycke
K. Jochumsen
B. Afsari
L. Danilova
D. A. Levine
K. Jardon
X. Zeng
J. Arseneau
L. Fu
L. A. Diaz
R. Karchin
C. Tomasetti
K. W. Kinzler
B. Vogelstein
A. N. Fader
L. Gilbert
N. Papadopoulos
Publicerad i Science Translational Medicine
Volym 10
Nummer/häfte 433
Sidor 1-9
ISSN 1946-6234
Publiceringsår 2018
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi
Sidor 1-9
Språk en
Ämneskategorier Cancer och onkologi, Obstetrik och gynekologi

Sammanfattning

We report the detection of endometrial and ovarian cancers based on genetic analyses of DNA recovered from the fluids obtained during a routine Papanicolaou (Pap) test. The new test, called PapSEEK, incorporates assays for mutations in 18 genes as well as an assay for aneuploidy. In Pap brush samples from 382 endometrial cancer patients, 81% [95% confidence interval (CI), 77 to 85%] were positive, including 78% of patients with early-stage disease. The sensitivity in 245 ovarian cancer patients was 33% (95% CI, 27 to 39%), including 34% of patients with early-stage disease. In contrast, only 1.4% of 714 women without cancer had positive Pap brush samples (specificity, ~99%). Next, we showed that intrauterine sampling with a Tao brush increased the detection of malignancy over endocervical sampling with a Pap brush: 93% of 123 (95% CI, 87 to 97%) patients with endometrial cancer and 45% of 51 (95% CI, 31 to 60%) patients with ovarian cancer were positive, whereas none of the samples from 125 women without cancer were positive (specificity, 100%). Finally, in 83 ovarian cancer patients in whom plasma was available, circulating tumor DNA was found in 43% of patients (95% CI, 33 to 55%). When plasma and Pap brush samples were both tested, the sensitivity for ovarian cancer increased to 63% (95% CI, 51 to 73%). These results demonstrate the potential of mutation-based diagnostics to detect gynecologic cancers at a stage when they are more likely to be curable.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?